Product Description
Cudetaxestat (BLD-0409) is a non-competitive autotaxin inhibitor with direct anti-fibrotic activity and differentiating characteristics that is expected to enter a planned phase 2 clinical trial in patients with idiopathic pulmonary fibrosis. (Sourced from: https://www.blademed.com/news/august-22-2022/)
Mechanisms of Action: Autotaxin Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: Orphan Drug - Scleroderma, General *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Blade Therapeutics
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Idiopathic Pulmonary Fibrosis
Phase 1: Healthy Volunteers|Fatty Liver, Alcoholic|Liver Diseases, Alcoholic|Hepatitis, Chronic|Hepatitis, Alcoholic|Non-alcoholic Steatohepatitis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| B-0409-104 | P1 |
Completed |
Healthy Volunteers |
2021-12-16 |
12% |
2022-04-16 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
| B-0409-103 | P1 |
Completed |
Healthy Volunteers |
2021-09-17 |
50% |
2022-05-18 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
| B-0409-102 | P1 |
Completed |
Healthy Volunteers |
2021-08-17 |
50% |
2021-11-11 |
|
| B-0409-101 | P1 |
Completed |
Hepatitis, Alcoholic|Fatty Liver, Alcoholic|Non-alcoholic Steatohepatitis|Hepatitis, Chronic|Liver Diseases, Alcoholic |
2020-12-03 |
50% |
2021-06-05 |
|
| B-0409-201 | P2 |
Unknown status |
Idiopathic Pulmonary Fibrosis |
2023-12-30 |
12% |
2024-05-02 |
Primary Endpoints|Treatments|Trial Status |